Vol 20, Supp. A (2024)
Case report
Published online: 2024-10-03
Effectiveness of rechallenge with BRAF/ /MEK inhibitors in patient with advanced melanoma with BRAF V600 mutation
DOI: 10.5603/ocp.102700
Abstract
Rechallenge with BRAF/MEK inhibitors is currently a recognized option that improves treatment outcomes in terms
of response and survival. This paper presents the case of a 54-year-old female patient with metastatic melanoma
and a positive BRAF mutation status. The patient received first line targeted therapy. After disease progression,
immunotherapy was administered. After another progression, with a good performance status, targeted therapy
was reintroduced. A good response was achieved with a statistically significant prolongation of survival. The patient,
without progression, in a good performance status, is alive 52 months after the start of the first line therapy
and 23 months after the start of rechallenge.
References
- Reschke R, Robin JC, Ziemer M. Rechallenge of targeted therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2019; 17(5): 483–486.
- Rutkowski P, Wysocki P, Kozak K. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract. 2022; 18(6): 357–392.
- Priantti JN, Vilbert M, Madeira T, et al. Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023; 15(15).
- de Miguel PA, Berciano-Guerrero MA, Muñoz-Couselo E, et al. Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801. J. Clin. Oncol. ; 41(16): 9547–9547.
- Cybulska-Stopa B, Rogala P, Czarnecka A, et al. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Research. 2020; 30(5): 465–471.
- Czarnecka A, Cybulska-Stopa B, Plachta I, et al. Long-term efficacy of BRAFi/MEKi rechallenge in metastatic melanoma: Report of 9 years of clinical practice. Journal of Clinical Oncology. 2023; 41(16_suppl): e21550–e21550.